Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00492869
Other study ID # CAEB071A2207
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date January 2007

Study information

Verified date September 2016
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Efficacy and safety of AEB071 in combination with mycophenolate acid sodium, basiliximab and steroids in preventing acute rejection after kidney transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion: - Male and female patients of any race 18 years or older - Adult recipients of kidney transplant from a deceased or living donor - Recipients of a functioning kidney within 24 hours post transplant Exclusion: - Need for medication prohibited by the protocol - Patients or donors infected with Hepatitis B,C or HIV - Patients with a history of cancer within last 5 years - Patients with history of significant cardiac disorder - Patients of high-risk immunological status Other protocol-defined inclusion/exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AEB071


Locations

Country Name City State
Belgium CHU Erasme Bruxelles
Belgium UZ Gasthuisberg Leuven
Canada Queen Elizabeth II Halifax
Canada Saint Joseph's Hospital Hamilton Ontario
Canada Hopital Maisonneuve-Rosemont Montreal Quebec
Germany Klinikum der Humboldt Universitat Charite Berlin
Germany Universitaetsklinik Charité Berlin
Germany Medizinische Hochschule Hannover Hannover
Germany Univ.-Klinikum Heidelberg Heidelberg
Germany Staedt. Kliniken Koeln-Merheim Koeln
Germany Klinikum der Universitaet Regensburg Regensburg
Spain Fundacion Puigvert Barcelona
Spain Hospital Juan Canalejo La Coruna
Sweden Enheten f Transpl och Leverkir, SU/Sahlgrenska Goteborg
Sweden Transplantationskirurgiska mottagningen, Akademiska Sjukhuse Uppsala
United Kingdom Addenbrookes Hospital Cambridge
United Kingdom Leicester General Hospital Leicester
United Kingdom Churchill Hospital Oxford
United States University of Michigan Health System Ann Arbor Michigan
United States U of Maryland Medical Center Baltimore Maryland
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Brigham and Women's Hospital Boston Massachusetts
United States University of Cincinnati, Dept of Internal Medicine Cincinnati Ohio
United States Baylor U Medical Center Dallas Texas
United States University of Colorado Health Science Center Denver Colorado
United States Henry Ford Hospital Transplant Institute Detroit Michigan
United States Duke University Medical Center Durham North Carolina
United States University of Texas Medical Branch at Galveston Galveston Texas
United States Saint Barnabas Medical Center Livingston New Jersey
United States USC Medical Center Los Angeles California
United States U of Wisconsin Hospital Clinics Madison Wisconsin
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Comprehensive Transplant Clinic New York New York
United States Mount Sinai Medical Center New York New York
United States University of Pennsylvania Health System-Presbyterian Medical Center Philadelphia Pennsylvania
United States University of Utah Salt Lake City Utah
United States University of California San Diego San Diego California
United States California Pacific Medical Center San Francisco California
United States UCSF San Francisco California
United States Lifelink, Inc. Tampa Florida
United States University of Toledo Health Science Campus Toledo Ohio

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Germany,  Spain,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy will be defined using a composite efficacy failure end point (treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up) between treatment and control arms
Secondary Renal function assessed by calculated and measured glomerular filtration rate (GFR). Incidence of Chronic Allograft Nephropathy using biopsies
See also
  Status Clinical Trial Phase
Recruiting NCT04910867 - APOL1 Genetic Testing Program for Living Donors N/A
Completed NCT02723591 - To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients Phase 4
Completed NCT05945511 - Silent Gallbladder Stone in Kidney Transplantation Recipients: Should it be Treated?
Completed NCT02234349 - Bile Acids and Incretins in Pancreas Kidney Transplant Patients N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4
Recruiting NCT05917795 - Endoscopic Sleeve Gastroplasty With Endomina® for the Treatment of Obesity in Kidney Transplant Candidates N/A
Not yet recruiting NCT05934383 - Safety and Efficacy of Ultrasound Renal Denervation in Kidney Transplantation Patients With Uncontrolled Hypertension N/A
Withdrawn NCT04936971 - Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response Phase 4
Not yet recruiting NCT04540640 - Oxygenated Machine Preservation in Kidney Transplantation N/A
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Terminated NCT02417870 - Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation Phase 1/Phase 2
Completed NCT02560558 - Bela 8 Week Dosing Phase 4
Recruiting NCT02154815 - Pre-emptive Kidney Transplantation Quality of Life N/A
Completed NCT02235571 - iChoose Decision Kidney Aid for End-Stage Renal Disease Patients N/A
Enrolling by invitation NCT01905514 - ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients N/A
Completed NCT02147210 - Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1 N/A
Recruiting NCT01699360 - The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients Phase 4
Completed NCT01655563 - Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation Phase 2
Completed NCT01672957 - ORANGE Study: An Observational Study on Renal Function in Kidney Transplant Patients on Immunosuppressive Therapy Containing CellCept (Mycophenolate Mofetil) N/A